

Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Fei Tong¹
Bo Dong¹
Rongkui Chai¹
Ke Tong^{2,3}
Yini Wang⁴
Shipiao Chen¹
Xinmei Zhou¹
Daojun Liu⁵

¹Department of Pathology and Pathophysiology, Provincial Key Discipline of Pharmacology, Jiaxing University Medical College, Jiaxing, Zhejiang, ²College of Life Science and Engineering, ³State Defense Key Laboratory of Fundamental Science on Nuclear Wastes and Environment, Southwest University of Science and Technology, Mianyang, Sichuan, ⁴Department of Nursing, Zhejiang Rongjun Hospital, The Third People's Hospital of Jiaxing, Jiaxing, Zhejiang, ⁵Department of Pharmacochimistry, Shantou University Medical College, Shantou, Guangdong, People's Republic of China

Abstract: The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-*b*-poly(gamma-benzyl L-glutamate) (PEG-*b*-PBLG₅₀) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Sprague Dawley rats were preconditioned with 20 mg/kg Sim or simvastatin/PEG-*b*-PBLG₅₀ (Sim/P) compounds, and then subjected to 45 min of ischemia and 1 h of reperfusion. The blood and small intestines were collected, serum levels of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor- α , and nitric oxide (NO) were checked, and the dry/wet intestine ratios, superoxide dismutase activity, myeloperoxidase content, reactive oxygen species, endothelial nitric oxide synthase, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38 mitogen-activated protein kinase (p38MAPK) expressions were measured in intestinal tissues. Both Sim and Sim/P pretreatment reduced intestinal oxidative damage, restricted inflammatory harm, and downregulated the BMP4 and COX-2 expressions as compared to II/RI groups, while Sim/P remarkably improved this effect.

Keywords: PEG-*b*-PBLG₅₀, II/RI, simvastatin, BMP4, COX-2

Introduction

Intestinal ischemia/reperfusion injury (II/RI) is a major pathophysiological phenomenon and a potentially life-threatening problem in clinical medicine.^{1,2} The mortality rates from II/RI are very high and reach more than 60% and it often requires clinical operation to cut off the necrotic intestinal segment.^{3,4} It causes the tissue injury through inadequate blood and oxygen supply relative to cellular energy stores exhaustion, tissue metabolic disorder, and toxic metabolites accumulation in intestinal ischemia phase and leads to reactive oxygen species (ROS), inflammatory factors, calcium overload, and so on, mediating the further damage of intestine in reperfusion phase.⁵ It is well known that oxygen supply reestablishment results in ROS production, causing lipid oxidation reaction in cell membranes,⁶ and blood supply reestablishment leads to production of a lot of inflammatory factors to aggravate tissue injury and intestinal barrier dysfunction, and toxic metabolite products enter the systemic blood circulation and threaten life.⁷

ROS is engendered on intestinal ischemia/reperfusion (I/R), and is one of the major reasons of intestinal damage.⁸ Previous studies have showed that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the key enzyme that is involved in ROS production.⁹ NADPH oxidase is composed of at least five protein components

Correspondence: Fei Tong
Department of Pathology and Pathophysiology, Provincial Key Discipline of Pharmacology, Jiaxing University Medical College, Jiaxing, Zhejiang, People's Republic of China
Email: tongxuchang@163.com

and three cytosolic components (including p47phox).¹⁰ p47phox is the subunit mainly responsible for transporting the cytosolic complex from the cytosol to the membrane in oxidase activation and impels ROS production.¹⁰ Many exogenous antioxidants (including superoxide dismutase [SOD]) aimed to reduce ROS damage have been studied in the treatment of I/R-induced intestinal injury.¹¹ More and more evidence has demonstrated that stimulation of endogenous antioxidant systems may be an important tactic for achieving intestinal protection on I/R injury.¹¹

The disorder of proinflammatory and anti-inflammatory factors boosts II/RI.¹ Proinflammatory factors including interleukin-6 (IL-6) and tumor necrosis factor (TNF- α) generated largely, and anti-inflammatory factors including interleukin-4 (IL-4) and interleukin-10 (IL-10) engendering insufficiently via damaged intestines and blood have been involved as the chief contributor of II/RI.^{12,13}

Bone morphogenetic protein 4 (BMP4) is one of the BMP families (including BMP2-BMP9).¹⁴ Previous studies have affirmed that BMP4 has a role with BMP receptors involving type I and type II¹⁵ and then adjusts physiopathologic process of bodies.^{16–18} Some documents have shown that BMP4 exacerbates exaggeration cardiac I/R injury.¹⁹ In addition, BMP4 is a proinflammatory gene that induces endothelium dysfunction, mediating abnormal expression of endothelial nitric oxide synthase (eNOS) and leads to impairment of vascular relaxation,²⁰ and that activates NADPH oxidase to induce ROS production and then improves the expression of cyclooxygenase-2 (COX-2) through p38 mitogen-activated protein kinase (p38MAPK).²¹ COX-2 promotes vasopermeability and aggravates tissues' damage.²¹

Many documents have attested that simvastatin (Sim) can protect the small intestine against (I/R) damnification.^{22–24} In the present study, we try to explore the protective effect of Sim on II/RI. As is well known, the in vivo solubility of Sim is very low and circulation time is very short.^{25–27} Here, a poly(ethylene glycol)-*b*-poly(γ -benzyl L-glutamate) (PEG-*b*-PBLG₅₀; P) block multipolymer (framework depicted in Figure 1) as a latent Sim nanoparticle is reported. The block multipolymer is synthesized through the ring-opening polymerization of BLG-*N*-carboxyanhydride (NCA) with PEG-NH₂ as the macroinitiator. The P and Sim integrate into a compound through hydrophobic functions. The encapsulated Sim shows stable release, which can promote the research on the protective action of Sim. Sim loading and in vitro release are confirmed. In vivo research is conducted through the hypodermic injection of the Sim/P compound to II/RI in rats, followed by the determination of serum IL-4, IL-6, IL-10, TNF- α , and nitric oxide (NO),




Figure 1 The structure of PEG-*b*-PBLG.

Note: "m" represents the degree of polymerization.

Abbreviation: PEG-*b*-PBLG, poly(ethylene glycol)-block poly(γ -benzyl L-glutamate).

measurements of SOD activity and methane dicarboxylic aldehyde (MDA) level in small intestinal tissues, and finally the ROS, eNOS, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38MAPK expressions in small intestinal tissues.

Materials and methods

Material

PEG-NH₂ (molecular weight, 5 kDa), dimethyl formamide (DMF), and BLG were bought from Aladdin (Shanghai, China); regenerative fiber dialysis bag (molecular weight cut off [MWCO], 3.5 kDa, 7 kDa) was bought from Union Carbide Company (Danbury, CT, USA); simvastatin was bought from Shangyu Hangzhou Jing Xin Pharmaceutical Co., Ltd; Hela cells were bought from Shanghai Forte Cheng Biological Technology Co., Ltd; other reagents were bought from Sigma.

Methods

Synthesis of PEG-*b*-PBLG₅₀

PEG-*b*-PBLG₅₀ was synthesized by following way: The ring-opening polymerization of BLG-*N*-carboxyanhydride with PEG-NH₂ as the macroinitiator obtained PEG-*b*-PBLG, as described in Figure 2. BLG-NCA was synthesized and characterized by a previously published method.²⁸ The right amount of PEG-NH₂ in 10 mL of DMF was mixed with a quantity of BLG-NCA/DMF fluid (0.1 g/mL) by vacuumization and nitrogen protection. The corresponding compounds were stirred at 40°C for 3 days and dialyzed for 3 days using dialysis tubing (MWCO, 7 kDa). The PEG-*b*-PBLG polymers were gained by freeze drying, the degree of polymerization of PBLG was 50, and they were characterized by ¹H-nuclear




Figure 2 (A) Synthesis of PEG-*b*-PBLG₅₀; (B) ¹H NMR spectra of PEG-*b*-PBLG₅₀ and its intermediates; (C) Gel permeation chromatograms of PEG-*b*-PBLG₅₀; (D) Fourier transform infrared spectroscopy of PEG-*b*-PBLG₅₀.

Abbreviations: DMF, N-dimethylformamide; ¹H NMR, ¹H-nuclear magnetic resonance; PEG-*b*-PBLG₅₀, poly(ethylene glycol)-*b*-poly(γ-benzyl L-glutamate); PEG-NH₂, poly(ethylene glycol) amine.

magnetic resonance, gel permeation chromatogram, and Fourier transform infrared spectroscopy.

Cytotoxicity evaluation of PEG-*b*-PBLG₅₀

The detailed method for the cytotoxicity evaluation of block copolymer PEG-*b*-PBLG₅₀ is referred to the technology and method specified in our previous article.²⁹

Encapsulation of simvastatin through PEG-*b*-PBLG₅₀

To assess the loading of simvastatin by PEG-*b*-PBLG₅₀, a certain amount of simvastatin (5 mg/mL) in phosphate buffered solution (PBS) (pH=7.2, 0.01 mmol/L; including 2% dimethyl sulfoxide) was mixed with PEG-*b*-PBLG₅₀ in a PB solution. And then the mixed solutions were transferred to a dialysis bag (MWCO, 7 kDa) and dialyzed. When the sunk polymer in the test was wholly removed, the polymer-loaded simvastatin was measured through high-performance liquid chromatography (HPLC) and transmission electron microscopy (TEM).

In vitro release of simvastatin from PEG-*b*-PBLG₅₀

Simvastatin releases from the PEG-*b*-PBLG₅₀ were detected by dialysis (MWCO, 7 kDa) at room temperature with 5 mL of simvastatin/PEG-*b*-PBLG₅₀ compound against 60 mL of 0.02 mol/L PB (pH 7.4). At 0.02-, 0.04-, 0.08-, 0.17-, 0.33-,

0.42-, 0.5-, 0.67-, 0.75-, 1-, 1.5-, 1.67-, 1.75-, 2-, 3-, and 4-day time interval, a certain amount of release mediums were retrieved and supplemented with a proper amount of fresh release mediums. The quantity of released simvastatin remaining in the dialysis bag was measured through HPLC. The free simvastatin releases in the absence of polymeric compound were also executed as a control.

Blood simvastatin concentration evaluation

The Sprague Dawley (SD) rats were administrated a dose of 20 mg/kg simvastatin (Sim) or simvastatin/PEG-*b*-PBLG₅₀ (Sim/P) by abdominal subcutaneous injection. Blood (0.2 mL) was extracted to put into heparinized tubes at specified time intervals. Blood was separated immediately by centrifugation (12,000× *g* for 15 min at 4°C) and stored under -80°C for the following analyses. The concentration of Sim and Sim/P in rat blood was measured by liquid chromatography tandem mass spectrometry following the previous methods.³⁰

The distribution of simvastatin/polymer compound in SD rats

The SD rats were administrated a dose of 20 mg/kg Sim or Sim/P by abdominal subcutaneous injection. The different tis-

sues were extracted and put into test tubes, where the miscible liquids containing 0.2 mL 60% perchloric acid and 0.2 mL 30% hydrogen peroxide were added. The samples were put into an 80°C water bath for 40–60 min and then the color of the samples became faint yellow. 0.2 mL of the tissues liquids were extracted to add 1 mL of scintillation solution and 3 mL of absolute ethyl alcohol, then the radioactivity of different tissues were checked by TRI-CARB2900 TR liquid scintillation counter (PACKARB) following previous methods.³¹

Animal and surgical procedures of I/R

SD rats (180–220 g) were accommodated by the Animal Research Center of Jiaying University Medical College, Jiaying, People's Republic of China. All the procedures and care administered to the animals had been approved by the Institutional Ethics Committee of Jiaying University Medical College. The investigation conformed to the guide for the care and use of laboratory animals published by the US National Institutes of Health (NIH Publication updated in 2011). In the research, 40 SD rats were assigned to four groups (each group including 10 rats): 1) Sham group; 2) I/R group: SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg) through intraperitoneal injection. The abdomina were opened and the arteriae mesenterica superior were separated to be clamped for 45 min by a small vessel clip, followed by 1 h of reperfusion; 3) simvastatin (Sim) group: Sim was administered once a day (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures; 4) simvastatin/PEG-*b*-PBLG₅₀ (Sim/P) group: Sim/P was administered once every 4 days (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures. The blood was collected from the abdominal aorta and centrifuged under 3,600× *g* for 20 min to gain the sera. A segment of small intestine of SD rats was removed to weigh the wet intestine and it was baked for 48 h under 80°C to weigh the dry intestine. A segment of small intestine was cut off right away and stored at –80°C until analysis.

SOD activity and MDA content evaluation

SOD activity and MDA content of intestinal tissues were checked using the previous methods.³² The intestines were collected after reperfusion for 1 h and the blood was purged drastically, homogenized (100 mg), and centrifuged at 3,600× *g* for 20 min to gain the liquid supernatant. SOD activity and MDA level were checked through xanthine oxidase and thiobarbituric acid method.³⁰ The absorbances were checked at 550 and 532 nm, respectively. Lipid peroxide contents are shown by “U” of SOD/mg pro and “nmol” of MDA/mg pro in tissues.

Evaluation of serum NO level

The methods have been described previously.³³ The blood was collected after reperfusion for 1 h and centrifuged at 3,600× *g* for 20 min to gain the liquid supernatant. The NO₂[–]/NO₃[–] content was measured by nitrate reductase and absorption photometry. The absorbances were checked at 550 nm. The content of NO₂[–]/NO₃[–] is shown in “μmol” of NO₂[–]/NO₃[–]/L serum.

Measurement of serum IL-4, IL-6, IL-10, and TNF-α content

The method was depicted mainly through previous reports.^{12,13} The sampling process was the same as above. The IL-4, IL-6, IL-10, and TNF-α contents were measured by double anti-sandwich ABC-ELISA method. The absorbances were checked at 450 and 492 nm, respectively. The levels of IL-4, IL-6, IL-10, and TNF-α were expressed in “ng” of IL-4, IL-6, IL-10, and TNF-α/L serum.

Evaluation of ROS

Previous methods have been referred to here.^{34–37} After 1 h of reperfusion, SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg), and CM-H₂DCFDA (100 μg) was injected into the intestinal circulation. After CM-H₂DCFDA injection, the small intestine was harvested for 45 min and dipped in 4% paraformaldehyde for about 24 h. After treatment with 20% sucrose for about 12 h, the small intestine was immediately frozen in liquid nitrogen. Cryostat sections were cut at –20°C and the sections were placed on Star-Frost adhesive slides and air-dried for about 3 min. Parts were washed in PBS and stained with DAPI for fluorescence microscopy analysis in ROS qualitative evaluation. ROS quantitative evaluation in isolated mitochondria was performed using the amplex red H₂O₂/peroxidase assay kit using a spectrofluorometer and emission wavelengths of 544 and 590 nm, respectively.

Western blot analysis

Previous methods have been referred to here.^{21,38–40} Briefly, small intestinal tissues were homogenized in protein lysate buffer. The homogenate was resolved on polyacrylamide sodium dodecyl sulfate gels, and electrophoretically transferred to polyvinylidene difluoride membranes. The membrane was blocked with 3% bovine serum albumin, and incubated with primary antibodies (Abs) against active eNOS, p47phox, p38MAPK, BMP4, COX-2, and subsequently with alkaline phosphatase-conjugated secondary Abs. It was developed via 5-*b*-romo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium. Blot was stained through anti-β-actin Ab, and the content of protein was normalized with respect to β-actin and density.

Immunohistochemical assessment

Previous methods have been referred to here.^{41–43} Sections with a thickness of 5 μm were obtained from the small intestine parts and mounted on poly-L-lysine-coated slides. The parts were immersed in 0.3% H_2O_2 for 20 min and washed with PBS. The parts were then incubated in rabbit anti-COX-2, anti-BMP4, and anti-p38MAPK polyclonal antiserum (Abcam, UK) for 1 h (1:100 dilution). After the primary incubation and three rinses in PBS, parts were incubated in biotinylated goat anti-rabbit IgG (Invitrogen, CA, USA) for 15 min (1:2,000 dilution). Following the incubation in substrate chromagen solution for 15 min, all parts were washed in PBS and distilled water, mounted in glycerol, and checked later under the microscope. The small intestinal parts stained positively for COX-2, BMP4, and p38MAPK were evaluated and compared among groups.

Statistical analysis

All experiments were repeated in triplicate. All the data were depicted as mean values \pm standard deviation. An analysis of

variance test and a Student's *t*-test usually assessed statistical significance. A value of <0.01 ($P < 0.01$) was regarded as statistically significant.

Results

Synthesis and characterization of PEG-*b*-PBLG₅₀

The PEG-*b*-PBLG was made up of a PEG block and aPBLG (Figure 1). In the current research, the molecular weight of PEG block was 5 kDa, and the degree of polymerization of the PBLG was 50. The synthesis was accomplished in a step order as depicted in Figure 2A. The ^1H NMR spectra of PEG-*b*-PBLG₅₀ is depicted in Figure 2B, and the characteristic proton peaks of both PEG and PBLG block were in existence, corroborating that the synthesis proceeded in a controlled way and was successful. The gel permeation chromatograms (GPCs) of PEG-*b*-PBLG are depicted in Figure 3 and the GPCs showed a sharp unimodal GPC peak, and the molecular weight of the termination product PEG-*b*-PBLG₅₀




Figure 3 Characterization of PEG-*b*-PBLG₅₀ and simvastatin/PEG-*b*-PBLG₅₀ complexes.

Notes: (A) TEM image of simvastatin/PEG-*b*-PBLG₅₀ complexes; (B) Cellular viability of EC9706 cells cultured with different concentrations of PEG-*b*-PBLG₅₀ and results expressed as mean \pm standard deviation; (C) Cumulative releasing profile of simvastatin from simvastatin/PEG-*b*-PBLG₅₀ complexes and results expressed as mean \pm standard deviation. (D) Blood simvastatin concentration of simvastatin and simvastatin/PEG-*b*-PBLG₅₀ complexes in rats and results expressed as mean \pm standard deviation.

Abbreviations: PEG-*b*-PBLG₅₀, poly(ethylene glycol)-*b*-poly(γ -benzyl L-glutamate); TEM, transmission electron microscopy.

gained from the GPC detection is listed in Table 1. The FT-IR of PEG-*b*-PBLG₅₀ is depicted in Figure 3D and the FT-IR showed that the absorption peaks at 1,734 and 1,167 cm⁻¹ were the ester linkage of PEG-*b*-PBLG₅₀ and the characteristic peaks at 1,652 and 1,547 cm⁻¹ were acid amides I and II, affirming that the synthesis proceeded successfully.

Cellular viability evaluation

The evaluation of cell toxicity from PEG-*b*-PBLG₅₀ on EC9706 cells was checked in 24-h culturing and the result is revealed in Figure 3B. The PEG-*b*-PBLG₅₀ showed low cell toxicity even below a concentration as high as 300 µg/mL.

Loading capacity of simvastatin in PEG-*b*-PBLG₅₀

Simvastatin could be efficiently loaded through PEG-*b*-PBLG₅₀ at physiological pH by the hydrophobic interaction. Simvastatin was added to PEG-*b*-PBLG₅₀ (mass ratio, 1:5) and dialyzed (MWCO, 7 kDa) against PB solution (pH 7.4, 0.01 mmol/L). The dialysis of free simvastatin as a control was also conducted at the same condition in a PB solution. To decide the load of simvastatin in PEG-*b*-PBLG₅₀, the quantity of simvastatin was checked by HPLC in the dialysate and deducted from the total quantity of added simvastatin. The load of simvastatin was 41.8% by calculating, expressed as the mass ratio of loaded simvastatin to the polymeric compound host (Table 1).

Characterization evaluation of simvastatin/polymer compound

The simvastatin/polymer compound was measured by TEM and the image is revealed in Figure 3A. The simvastatin/polymer compound showed an orbicular structure and the diameter was ~73 nm (Table 1).

In vitro release of simvastatin from PEG-*b*-PBLG₅₀

The simvastatin release from PEG-*b*-PBLG₅₀ was measured by dialysis (MWCO, 7 kDa) under room temperature, with

Table 1 Molecular weights, polydispersities, TEM, and simvastatin-loading capacity of PEG-*b*-PBLG₅₀

Sample	M _n (kDa)/ ¹ H NMR	M _n (kDa)/GPC	PDI	TEM (nm)	Loading capacity (%)
P	28.6	18.7	1.99	NA	NA
Sim/P	NA	NA	NA	73	41.8

Abbreviations: ¹H NMR, ¹H-nuclear magnetic resonance; GPC, gel permeation chromatograms; M_n, number-average molecular weight; NA, not applicable; PDI, polydispersity index; TEM, transmission electron microscopy.

5 mL of simvastatin/PEG-*b*-PBLG₅₀ against a PB solution of 0.02 mol/L (pH of 7.4). The release curve of simvastatin/PEG-*b*-PBLG₅₀ is depicted in Figure 3C. After 2 h, ~48.94% of the simvastatin was released from simvastatin/PEG-*b*-PBLG₅₀, manifesting the beginning of a burst release of simvastatin. Approximately 67.72% of the simvastatin was released after 2 days and ~97% after 4 days, manifesting biphasic release profile from simvastatin/PEG-*b*-PBLG₅₀.

Plasma simvastatin concentration evaluation

It is shown in Figure 3D. The concentration of simvastatin in the plasma of SD rats following a single subcutaneous injection in Sim group at a dose of 20 mg/kg rapidly reached C_{max} of 163.56 ng/mL at a T_{max} of 2 h, and declined to baseline values within 10 h of administration. The plasma concentration of SD rats following a single subcutaneous injection in Sim/P group at a dose of 20 mg/kg reached C_{max} of 41.25 ng/mL at a T_{max} of 2 h, and declined to baseline values within 4 days of administration. These results showed that the release of simvastatin from Sim/P group was substantially sustained compared to Sim group.

In vivo distribution evaluation of simvastatin/PEG-*b*-PBLG₅₀ compound

It is depicted in Figure 4. The disintegrations per minute (DPM) of spleen was maximum and then was kidney and heart. However, the DPM of intestine, lung, and liver was minimum. This showed that a part of simvastatin from simvastatin/PEG-*b*-PBLG₅₀ compound was swallowed by the phagocyte of spleen, but was not swallowed by the phagocyte of liver, then a part of simvastatin from simvastatin/PEG-*b*-PBLG₅₀ compound accumulated in the kidney, heart,




Figure 4 The distribution of simvastatin/polymer compound in rats.

Note: The distribution of simvastatin/PEG-*b*-PBLG₅₀ in rats and results expressed as mean ± standard deviation.

Abbreviation: DPM, disintegrations per minute.

intestine, and so on. The result showed that simvastatin-loaded PEG-*b*-PBLG₅₀ could avoid liver metabolism.

Measurement of SOD activity and MDA content

As shown in Figure 5A and B, SOD activity in intestinal tissue in I/R group rats was less than that in the Sham group ($P<0.01$). SOD activity in intestinal tissue reached 156.78 ± 1.24 U in Sham group, whereas SOD activity in intestinal tissue in I/R group reached 105.63 ± 2.78 U. Administration of simvastatin increased SOD activity (128.96 ± 1.05 U) in intestinal tissues, compared with SOD activity in intestinal tissues in the I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably increased SOD activity (139.03 ± 1.23 U), which was remarkably higher than that in the I/R group ($P<0.01$); MDA level in intestinal tissue in I/R group rats was greater than in Sham group ($P<0.01$). MDA content in intestinal tissue reached 0.33 ± 0.08 nmol in Sham group, whereas MDA content in intestinal tissue in I/R group reached 0.71 ± 0.02 nmol. Administration of simvastatin decreased MDA content (0.51 ± 0.06 nmol) in intestinal tissue, compared with the MDA content in intestinal tissue in the I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably decreased MDA content (0.42 ± 0.04 nmol), which was remarkably lower than that in the I/R group ($P<0.01$).

Measurement of serum IL-4, IL-6, IL-10, and TNF- α level

As shown in Figure 5C, IL-4 content in serum in I/R group rats was higher than that in the Sham group ($P<0.01$). IL-4 content in serum reached 4.19 ± 0.38 ng in Sham group, whereas IL-4 content in serum in I/R group reached 15.27 ± 0.71 ng. Administration of simvastatin decreased IL-4 content (11.32 ± 0.59 ng) in serum, compared with the IL-4 content in serum in the I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably decreased IL-4 content (8.08 ± 0.95 ng), which was remarkably lower than that in the I/R group ($P<0.01$); IL-6 content in serum in I/R group rats was greater than that in the Sham group ($P<0.01$). IL-6 level in serum reached 19.36 ± 1.01 ng in Sham group, whereas IL-6 content in serum in I/R group reached 50.03 ± 1.22 ng. Administration of simvastatin decreased IL-6 content (39.85 ± 0.98 ng) in serum, compared with IL-6 content in serum in I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably decreased IL-6 level (28.96 ± 1.15 ng), which was remarkably lower than that in the I/R group ($P<0.01$); IL-10 content in serum

in I/R group rats was greater than that in the Sham group ($P<0.01$). IL-10 content in serum reached 14.65 ± 1.23 ng in Sham group, whereas IL-10 content in serum in I/R group reached 47.53 ± 2.21 ng. Administration of simvastatin increased IL-6 level (60.03 ± 2.76 ng) in serum, compared with IL-10 content in serum in the I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably increased IL-10 content (78.85 ± 3.01 ng), which was remarkably greater than that in the I/R group ($P<0.01$); TNF- α content in serum in I/R group rats was greater than that in the Sham group ($P<0.01$). TNF- α content in serum reached 16.74 ± 1.32 ng in Sham group, whereas TNF- α content in serum in I/R group reached 89.23 ± 2.88 ng. Administration of simvastatin decreased TNF- α content (70.66 ± 1.78 ng) in serum, compared with TNF- α content in serum in I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably decreased TNF- α content (54.15 ± 1.36 ng), which was remarkably lower than that in I/R group ($P<0.01$).

Measurement of NO₂⁻/NO₃⁻ content and dry/wet intestine ratios

As shown in Figure 5D and E, NO₂⁻/NO₃⁻ content in serum in I/R group rats was lower than that in the Sham group ($P<0.01$). NO₂⁻/NO₃⁻ content in serum reached 24.27 ± 1.08 μ mol in Sham group, whereas NO₂⁻/NO₃⁻ content in serum in I/R group reached 7.8 ± 1.11 μ mol. Administration of simvastatin increased NO₂⁻/NO₃⁻ content (9.1 ± 0.87 μ mol) in serum, compared with NO₂⁻/NO₃⁻ content in serum in I/R group rats ($P<0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably increased NO₂⁻/NO₃⁻ content (12.3 ± 0.65 μ mol), which was remarkably greater than that in the I/R group ($P<0.01$); the dry/wet (D/W) intestine ratios in I/R groups rats were lower than those in Sham group ($P<0.01$). The D/W intestine ratios reached 3.08 ± 0.06 in Sham group, whereas the D/W intestine ratios in I/R groups reached 6.25 ± 0.09 . Administration of simvastatin increased the D/W intestine ratios (5.17 ± 0.08) compared with the D/W intestine ratios in I/R group rats ($P<0.01$), whereas administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably increased the D/W intestine ratios (4.46 ± 0.10), which were remarkably higher than those in I/R group ($P<0.01$).

ROS analysis

Fluorescence microscopy images of intestine parts are shown in Figure 6. CM-H₂DCFDA-positive cells were absent in intestinal tissue parts from Sham group. I/R group augmented mitochondrial ROS production, as affirmed through significant epithelial cell staining (CM-H₂DCFDA fluorescence) of




Figure 5 (A) SOD activity; (B) MDA level; (C) Level of IL-4, IL-6, IL-10, and TNF-α; (D) D/W intestine ratios; (E) Level of serum NO₂⁻/NO₃⁻.

Notes: The intestinal tissues and serum of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the level of SOD, MDA, IL-4, IL-6, IL-10, TNF-α, D/W intestine ratios, and NO₂⁻/NO₃⁻ measured. Results are expressed as mean ± standard deviation. (A) A significant decrease from Sham group is denoted by **P*<0.01, an increase from I/R group is denoted by ***P*<0.01, and a significant increase from I/R group is denoted by ****P*<0.01. (B) A significant increase from Sham group is denoted by **P*<0.01, a decrease from I/R group is denoted by ***P*<0.01, and a significant decrease from I/R group is denoted by ****P*<0.01. (C) A significant increase from Sham group is denoted by **P*<0.01, an increase from I/R group is denoted by ***P*<0.01, and a significant increase from I/R group is denoted by ****P*<0.01 (IL-4 and IL-10); a significant increase from Sham group is denoted by **P*<0.01, a decrease from I/R group is denoted by ***P*<0.01, and a significant decrease from I/R group is denoted by ****P*<0.01 (IL-6 and TNF-α). (D) A significant increase from Sham group is denoted by **P*<0.01, a decrease from I/R group is denoted by ***P*<0.01, and a significant decrease from I/R group is denoted by ****P*<0.01. (E) A significant decrease from Sham group is denoted by **P*<0.01, an increase from I/R group is denoted by ***P*<0.01, and a significant increase from I/R group is denoted by ****P*<0.01.

Abbreviations: D/W, dry/wet; I/R, ischemia/reperfusion; IL-10, interleukin-10; MDA, methane dicarboxylic aldehyde; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α; Sim, simvastatin; Sim/P, simvastatin/PEG-b-PBLG₅₀.




Figure 6 Expression of ROS in different groups of rats.

Notes: The intestinal tissues of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the expression of ROS measured. ROS expression in I/R group rats was higher than that in the Sham group; ROS expression in Sim group rats was less than that in the I/R group; ROS expression in Sim/P group rats was significantly less than that in the I/R group.

Abbreviations: I/R, ischemia/reperfusion; ROS, reactive oxygen species; Sim, simvastatin; Sim/P, simvastatin/PEG-*b*-PBLG₅₀.

intestine tissue parts. Sim/P group significantly reduced ROS production, compared with production of ROS in I/R group.

Western blot evaluation

eNOS, p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissues were checked by Western blot following the previously published method.^{21,38–40} The qualitative and quantitative outcomes are evaluated in Figure 7. The eNOS expressions in intestinal tissue in I/R group were greater than those in Sham group ($P < 0.01$). Administration of simvastatin upregulated the eNOS expressions in intestinal tissue, compared with eNOS expressions by I/R group ($P < 0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably upregulated eNOS expressions, compared with those in I/R group ($P < 0.01$).

The p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue in I/R group were greater than those in Sham group ($P < 0.01$). Administration of simvastatin downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue, compared with p47phox, p38MAPK, BMP4, and COX-2 expressions in I/R groups ($P < 0.01$). Administration of simvastatin/PEG-*b*-PBLG₅₀ remarkably downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions, compared with those in I/R group ($P < 0.01$).

Immunohistochemical analysis

As shown in Figure 8, expressions of COX-2, BMP4, and p38MAPK in intestinal tissues that were induced by I/R are greater than those in Sham group. Administration of simvastatin downregulated COX-2, BMP4, and p38MAPK expressions in intestinal tissue, compared with COX-2, BMP4, and p38MAPK expressions in intestinal tissue by induced I/R group, whereas administration of simvastatin/PEG-*b*-PBLG₅₀ downregulated COX-2, BMP4, and p38MAPK expressions, which were remarkably lower than in the I/R group.

Discussion

This is the first research to reveal that simvastatin and simvastatin/PEG-*b*-PBLG₅₀ pretreatment can both weaken intestine injury induced by intestinal I/R. We discovered that intestinal inflammatory reaction is remarkably mitigated after simvastatin and simvastatin/PEG-*b*-PBLG₅₀ preconditioning. The protective action is partially downregulated with BMP4 and COX-2, manifesting that the underlying mechanisms are associated with either BMP4 and COX-2-dependent or -independent pathways.

The intestinal mucosal injury is a major factor contributing to the pernicious complications of intestinal II/RI.⁴⁴ It is a well-known phenomenon that ROS-induced lipid peroxidation, proinflammatory and anti-inflammatory imbalance, and disorder of nitroso-redox balance lead to intestinal injury.^{12,22,45} Previous documents have also demonstrated that powerful oxidative stress starting in the epithelium upon recovery of blood cell circulations is a primary reason of necrosis of the intestinal epithelium on I/R-induced injury.⁴⁶ In the present study, we demonstrate that simvastatin and simvastatin/PEG-*b*-PBLG₅₀ pretreatment ameliorate oxidative stress damage, baste inflammatory response, and restore nitroso-redox balance (Figures 5, 6, and 7A).

In the study, we find that on II/RI rats, the protein contents and expression of BMP4 are augmented, and then p38MAPK and oxidative stress are activated, leading to upregulation of COX-2 protein levels and expression, where the pathway contributes to augmentation of II/RI. Simvastatin and simvastatin/PEG-*b*-PBLG₅₀ interestingly reverse the activation of the above pathway (Scheme 1). This also shows that BMP4 can enhance NADPH oxidase to promote NADPH oxidase subtype (including p47phox) expression, resulting in COX-2 expression upregulation through p38MAPK-dependent mechanism in our research. In our study, we found that simvastatin and simvastatin/PEG-*b*-PBLG₅₀ attenuate BMP4, COX-2, p47phox, p38MAPK, and ROS




Figure 7 Expression of eNOS (A), p47phox (B), p38MAPK (C), BMP4, and COX-2 (D) in different groups of rats.

Notes: The intestinal tissues of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the expressions of eNOS, p47phox, p38MAPK, BMP4, and COX-2 measured. Results are expressed as mean \pm standard deviation. (A) A significant increase from Sham group is denoted by * $P < 0.01$, an increase from I/R group is denoted by ** $P < 0.01$, and a significant increase from I/R group is denoted by *** $P < 0.01$. (B) A significant increase from Sham group is denoted by * $P < 0.01$, a decrease from I/R group is denoted by ** $P < 0.01$, and a significant decrease from I/R group is denoted by *** $P < 0.01$. (C) A significant increase from Sham group is denoted by * $P < 0.01$, a decrease from I/R group is denoted by ** $P < 0.01$, and a significant decrease from I/R group is denoted by *** $P < 0.01$. (D) A significant increase from Sham group is denoted by * $P < 0.01$, a decrease from I/R group is denoted by ** $P < 0.01$, and a significant decrease from I/R group is denoted by *** $P < 0.01$.

Abbreviations: BMP4, bone morphogenetic protein 4; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; I/R, ischemia/reperfusion; p38MAPK, p38 mitogen-activated protein kinase; p47phox, protein 47 kDa phagocyte oxidase; Sim, simvastatin; Sim/P, simvastatin/PEG-b-PBLG₅₀.





Figure 8 Expression of COX-2 (A), BMP4 (B), and p38MAPK (C) in different groups of rats.

Notes: The intestinal tissues of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the expression of ROS measured. COX-2, BMP4, and p38MAPK expressions in I/R group rats were higher than those in Sham group; COX-2, BMP4, and p38MAPK expressions in Sim group rats were less than those in I/R group; COX-2, BMP4, and p38MAPK expressions in Sim/P group rats were significantly less than those in I/R group.

Abbreviations: BMP4, bone morphogenetic protein 4; COX-2, cyclooxygenase-2; I/R, ischemia/reperfusion; p38MAPK, p38 mitogen-activated protein kinase; Sim, simvastatin; Sim/P, simvastatin/PEG-b-PBLG₅₀.



Scheme 1 Graphical representation of the ameliorative effect of simvastatin/PEG-*b*-PBLG₅₀ on II/RI.

Notes: Red arrow represents damage process; blue arrow represents mitigation process of damage.

Abbreviations: BMP4, bone morphogenetic protein; p47phox, protein 47 kDa phagocyte oxidase; PEG-*b*-PBLG₅₀, poly(ethylene glycol)-*b*-poly(γ-benzyl L-glutamate); ROS, reactive oxygen species; p38MAPK, p38 mitogen-activated protein kinase; COX-2, Cyclooxygenases-2; II/RI, intestinal ischemia/reperfusion injury.

expression. All of the above experimental results attest that BMP4/ROS/p38MAPK/COX-2 pathway is involved in II/RI. These results are in agreement with other documents.²¹ To sum up, our present research reveals that simvastatin and simvastatin/PEG-*b*-PBLG₅₀ preconditioning can provide intestine protection after II/RI through downregulating BMP4/COX-2 pathway, whereas simvastatin/PEG-*b*-PBLG₅₀ significantly improves the effect.

In addition, there are some limitations in our research. In our tests, the HE staining is not measured owing to the limited number of mice. On the other hand, we only found the association between simvastatin and simvastatin/PEG-*b*-PBLG₅₀ and the BMP4/ROS/p38MAPK/COX-2 pathway. The exact mechanism of how simvastatin and simvastatin/PEG-*b*-PBLG regulate the above pathway needs to be further explored.

Conclusion

The synthesized PEG-*b*-PBLG₅₀ can evidently enhance the bioactivity of simvastatin, and the distribution experiment shows that simvastatin/PEG-*b*-PBLG₅₀ can escape liver phagocytosis to improve the circulation time of simvastatin in vivo. The observational protective effect can be due to the antioxidative stress, anti-inflammatory properties, and the regulation of BMP4/COX-2 pathway by simvastatin/PEG-*b*-PBLG₅₀ in rats as compared to free simvastatin. Further detailed research is required to probe the underlying mechanisms of simvastatin/PEG-*b*-PBLG₅₀ on II/RI in rats.

Acknowledgment

This study was financially supported by the Department of Education, Zhejiang Government under Key Research Program.

Author contributions

All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sukhotnik I, Nissimov N, Ben Shahr Y, et al. Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia–reperfusion injury in a rat. *Pediatr Surg Int*. 2016;32(12):1193–1200.
2. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. *Ann Surg*. 1992;216(2):117–134.
3. Cámara CR, Guzmán FJ, Barrera EA, et al. Ketamine anesthesia reduces intestinal ischemia/reperfusion injury in rats. *World J Gastroenterol*. 2008;14(33):5192–5196.
4. Chang RW, Chang JB, Longo WE. Update in management of mesenteric ischemia. *World J Gastroenterol*. 2006;12(20):3243–3247.
5. Slijper N, Sukhotnik I, Chemodanov E, et al. Effect of simvastatin on intestinal recovery following gut ischemia-reperfusion injury in a rat. *Pediatr Surg Int*. 2010;26(1):105–110.
6. Moore RM, Muir WW, Granger DN. Mechanisms of gastrointestinal ischemia-reperfusion injury and potential therapeutic interventions: a review and its implications in the horse. *J Vet Intern Med*. 1995;9(3):115–132.
7. Khanna A, Rossman J, Caty MG, Fung HL. Beneficial effects of intraluminal nitroglycerin in intestinal ischemia-reperfusion injury in rats. *J Surg Res*. 2003;114(1):15–24.
8. Wang G, Yao J, Li Z, et al. miR-34a-5p inhibition alleviates intestinal ischemia/reperfusion-induced reactive oxygen species accumulation and apoptosis via activation of SIRT1 signaling. *Antioxid Redox Signal*. 2016;24(17):961–973.
9. Nakagiri A, Sunamoto M, Murakami M. NADPH oxidase is involved in ischaemia/reperfusion-induced damage in rat gastric mucosa via ROS production-role of NADPH oxidase in rat stomachs. *Inflammopharmacology*. 2007;15(6):278–281.
10. Babior BM. NADPH oxidase: an update. *Blood*. 1999;93(5):1464–1476.
11. Luo L, Li YC, Dai XZ, et al. Effects of proanthocyanidins on intestinal motility disturbance following intestinal ischemia/reperfusion. *J Invest Surg*. 2016;29(6):335–342.
12. Farmer DG, Shen XD, Amersi F, et al. CD62 blockade with P-Selectin glycoprotein ligand-immunoglobulin fusion protein reduces ischemia-reperfusion injury after rat intestinal transplantation. *Transplantation*. 2005;79(1):44–51.
13. Shu X, Zhang J, Wang Q, Xu Z, Yu T. Glutamine decreases intestinal mucosal injury in a rat model of intestinal ischemia-reperfusion by downregulating HMGB1 and inflammatory cytokine expression. *Exp Ther Med*. 2016;12(3):1367–1372.
14. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors*. 2004;22(4):233–241.
15. Upton PD, Long L, Trembath RC, Morrell NW. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells. *Mol Pharmacol*. 2008;73(2):539–552.

16. Lee J, Stavropoulos A, Susin C, Wikesjö UME. Periodontal regeneration: focus on growth and differentiation factors. *Dental Clin North Am*. 2010;54(1):93–111.
17. Vukicevic S, Paralkar VM, Cunningham NS, Gutkind JS, Reddi AH. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. *Dev Biol*. 1990;140(1):209–214.
18. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair-part A: current challenges in BMP delivery. *Biotechnol Lett*. 2009;31(12):1817–1824.
19. Gu GL, Yang QY, Zeng RL, Xu XL. The association between BMP4 gene polymorphism and its serum level with the incidence of LVH in hypertensive patients. *J Transl Med*. 2015;13:14.
20. Csizsar A, Labinskyy N, Jo H, Ballabh P, Ungvari Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. *Am J Physiol Heart Circ Physiol*. 2008;295(2):H569–H577.
21. Xiao L, Dong JH, Jin S, et al. Hydrogen sulfide improves endothelial dysfunction via downregulating BMP4/COX-2 pathway in rats with hypertension. *Oxid Med Cell Longev*. 2016;2016:8128957.
22. Hajipour B, Somi MH, Saberifar F, et al. Simvastatin attenuates intestinal ischemia/reperfusion induced injury in rat. *Folia Morphol (Warsz)*. 2009;68(3):156–162.
23. Slijper N, Sukhotnik I, Chemodanov E, et al. Effect of simvastatin on intestinal recovery following gut ischemia-reperfusion injury in a rat. *Pediatr Surg Int*. 2010;26(1):105–110.
24. Pirat A, Zeyneloglu P, Aldemir D, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. *Anesth Analg*. 2006;102(1):225–232.
25. Yasugi K, Nagasaki Y, Kato M, Kataoka K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. *J Control Release*. 1999;62(1–2):89–100.
26. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. *J Anat*. 1996;189:503–505.
27. Sharma D, Chelvi TP, Kaur J, et al. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. *Oncol Res*. 1996;8(7–8):281–286.
28. Hideharu M, Mizuki I, Satoko I, Takeshi E. Ring-opening polymerization of γ -benzyl-L-glutamate-N-carboxyanhydride in ionic liquids. *Polymer*. 2007;48:5867–5877.
29. Tong F, Tang X, Li X, Xia W, Liu D. The effect of insulin-loaded linear poly(ethylene glycol)-brush-like poly(L-lysine) block copolymer on renal ischemia/reperfusion-induced lung injury through downregulating hypoxia-inducible factor. *Int J Nanomedicine*. 2016;11:1717–1730.
30. Zhang Z, Bu H, Gao Z, Huang Y, Gao F, Li Y. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. *Int J Pharm*. 2010;394(1–2):147–153.
31. Li S, Jiang WQ, Wang AX, Guan ZZ, Zhang L, Pan SR. Releasing characterization, pharmacokinetics and distribution of PEG-PBLG copolymer micelles in vitro and in vivo. *Chinese Pharm J*. 2005;40(9):699–702.
32. Shi H, Li R, Qiang J, Li Y, Wang L, Sun R. Computed tomography perfusion imaging detection of microcirculatory dysfunction in small intestinal ischemia-reperfusion injury in a porcine model. *PLoS One*. 2016;11(7):e0160102.
33. Bentur OS, Chernichovski T, Ingber M, Weinstein T, Schwartz IF. Dimethyl sulfoxide attenuates nitric oxide generation via modulation of cationic amino acid transporter-1 in human umbilical vein endothelial cells. *Cryobiology*. 2016;73(2):226–231.
34. Kristiansen KA, Jensen PE, Møller IM, Schulz A. Monitoring reactive oxygen species formation and localisation in living cells by use of the fluorescent probe CM-H(2)DCFDA and confocal laser microscopy. *Physiol Plant*. 2009;136(4):369–383.
35. Oparka M, Walczak J, Malinska D, et al. Quantifying ROS levels using CM-H2DCFDA and HyPer. *Methods*. 2016;109:3–11.
36. Tan X, Zhang L, Jiang Y, et al. Postconditioning ameliorates mitochondrial DNA damage and deletion after renal ischemic injury. *Nephrol Dial Transplant*. 2013;28(11):2754–2765.
37. Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. *Kidney Int*. 2004;65(5):1714–1723.
38. Naito Y, Katada K, Takagi T, et al. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. *World J Gastroenterol*. 2006;12(13):2024–2030.
39. Li X, Schwacha MG, Chaudry IH, Choudhry MA. Heme oxygenase-1 protects against neutrophil-mediated intestinal damage by down-regulation of neutrophil p47phox and p67phox activity and O₂- production in a two-hit model of alcohol intoxication and burn injury. *J Immunol*. 2008;180(10):6933–6940.
40. Zhang CP, Li XC, Tang RX, Li XY, Zheng KY, Zeng LY. Effects of p38MAPK inhibitor on the occurrence of acute GVHD and intestine damage after allogeneic hematopoietic stem cell transplantation in mice. *Zhonghua Xue Ye Xue Za Zhi*. 2013;34(8):673–678.
41. Tarantino U, Scimeca M, Piccirilli E, et al. Sarcopenia: a histological and immunohistochemical study on age-related muscle impairment. *Aging Clin Exp Res*. 2015;27(Suppl 1):S51–S60.
42. Ouyang J, Zhang ZH, Zhou YX, et al. Up-regulation of tight-junction proteins by p38 mitogen-activated protein Kinase/p53 inhibition leads to a reduction of injury to the intestinal mucosal barrier in severe acute pancreatitis. *Pancreas*. 2016;45(8):1136–1144.
43. Han YM, Park JM, Cha JY, Jeong M, Go EJ, Hahm KB. Endogenous conversion of ω -6 to ω -3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/ β -catenin signaling or activating 15-PGDH/IL-18. *Int J Cancer*. 2016;138(9):2247–2256.
44. Zu G, Yao J, Ji A, et al. Nurr1 promotes intestinal regeneration after ischemia/reperfusion injury by inhibiting the expression of p21 (Waf1/Cip1). *J Mol Med (Berl)*. 2017;95(1):83–95.
45. Chen CF, Leu FJ, Chen HI, Wang D, Chou SJ. Ischemia/reperfusion-induced low reactivity of the rat superior mesenteric vascular bed is associated with expression of nitric oxide synthases. *Transplant Proc*. 2006;38(7):2216–2220.
46. Gordeeva AE, Temnov AA, Charnagalov AA, Sharapov MG, Fesenko EE, Novoselov VI. Protective effect of peroxiredoxin 6 in ischemia/reperfusion-induced damage of small intestine. *Dig Dis Sci*. 2015;60(12):3610–3619.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.